Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis

International Journal of Cancer

Volumn 140, Issue 5, 2017, Pages 1042-1049

  Manthravadi, Sashidhar ^a   Paleti, Swathi ^b   Pandya, Prashant ^b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c Children's Mercy Kansas City   (United States)

Author keywords

hepatitis C; hepatocellular carcinoma; meta analysis; sustained viral response

Indexed keywords

INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTERIAL EMBOLIZATION; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; FOLLOW UP; HEPATITIS C; HUMAN; INTERFERON BASED THERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; NEWCASTLE-OTTAWA SCALE; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; TRANSARTERIAL EMBOLIZATION; AGED; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS C, CHRONIC; LIVER NEOPLASMS; LIVER RESECTION; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; REMISSION; VIREMIA; VIROLOGY; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; VIRAL LOAD; VIREMIA;

EID: 85010469722     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30521     Document Type: Article

References (43)

1. Altekruse SF, Henley SJ, Cucinelli JE, et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am. J. Gastroenterol. 2014;109:542–53.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
3. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 2014;60:1767–75.
4. Ulahannan SV, Duffy AG, McNeel TS, et al. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology 2014;60:1637–44.
5. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006;243:229–35.
6. Zhou Y, Zhao Y, Li B, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 2010;10:78.
7. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529–38.
8. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329–37.
9. Hsu CS, Chao YC, Lin HH, et al. Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma. Sci Rep 2015;5:9954.
10. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55.
11. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
12. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–12.
13. Borenstein M, Hedges LV, Higgins J, et al. Introduction to meta-analysed. Wiley Online Library, 2009.
14. Wells G, Shea B, O'connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2000.
15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
16. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol 2011;64:1294–302.
17. Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2014.
18. Akamatsu M, Yoshida H, Shiina S, et al. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver Int 2006;26:536–42.
19. Harada N, Hiramatsu N, Oze T, et al. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma—a retrospective multicenter study. J Med Virol 2015;87:1199–206.
20. Hung CH, Lee CM, Wang JH, et al. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005;20:1553–9.
21. Jeong SC, Aikata H, Katamura Y, et al. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007;13:5343–50.
22. Joko K, Goto T, Watanabe H, et al. Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group. Hepatol Res 2016;46:251–8.
23. Kanogawa N, Ogasawara S, Chiba T, et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol 2015;30:1197–204.
24. Miyatake H, Kobayashi Y, Iwasaki Y, et al. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Digest Dis Sci 2012;57:1092–101.
25. Sakae M, Kubo S, Takemura S, et al. Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2012;42:564–73.
26. Sugimachi K, Kinjo N, Ikebe M, et al. Significance of hepatic resection for hepatocellular carcinoma with sustained virological response to interferon therapy for chronic hepatitis C. Hepatol Res 2013;43:605–9.
27. Tsujita E, Maeda T, Kayashima H, et al. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma. Hepato Gastroenterol 2015;62:157–63.
28. Huang JF, Yeh ML, Yu ML, et al. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. J Gastroenterol Hepatol 2015;30:1768–74.
29. Zhang N, Li F, Liu J, et al. Antiviral therapy improves outcomes in patients with small hepatocellular carcinoma and chronic hepatitis C virus infection treated with RFA. J Hepatol 2014;60:S406.
30. Tsuchiya K, Asano Y, Tamaki N, et al. Clinical impact of achieving sustained virological response in hepatitis C virus-infected patients with early stage hepatocellular carcinoma. J Hepatol 2015;62:S455–S56.
31. Di Donato R, Vukotic R, Badalamenti MR, et al. A case-control study evaluating the efficacy of antiviral therapy as secondary prophylaxis of hepatocellular carcinoma (HCC) recurrence after curative treatment in subjects with HCV-related cirrhosis. J Hepatol 2013;58(Supp 1):S109.
32. Furusyo N, Murata M, Ogawa E, et al. Reduction of hepatocellular carcinoma recurrence by pegylated interferon alpha-2b plus ribavirin treatment for chronic hepatitis C patients. Int J Antimicrob Agents 2013;42(Supp 2):S130.
33. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299–306.
34. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543–54.
35. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963–7.
36. Miyaguchi S, Watanabe T, Takahashi H, et al. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepato Gastroenterol 2002;49:724–9.
37. Wang Y, Luo Q, Li Y, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One 2014;9:e84484.
38. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.
39. McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011;30:1969–83.
40. Miyake Y, Takaki A, Iwasaki Y, et al. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010;17:287–92.
41. Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007;5:932–7.
42. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344–54.
43. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373:2618–28.